| screen_phc_ke | n | percent |
|---|---|---|
| Rhodes | 781 | 56.8% |
| Karen | 368 | 26.8% |
| Riruta | 226 | 16.4% |
| Total | 1375 | 100.0% |
Participants Gender & Site Data
| screen_phc_ke | Female | Male |
|---|---|---|
| Rhodes | 43.1% (337) | 56.9% (444) |
| Karen | 53.5% (197) | 46.5% (171) |
| Riruta | 59.7% (135) | 40.3% (91) |
| Total | 48.7% (669) | 51.3% (706) |
The table below show the total number of participnats screened this week
| screen_phc_ke | n | percent |
|---|---|---|
| Rhodes | 17 | 43.6% |
| Karen | 12 | 30.8% |
| Riruta | 10 | 25.6% |
| Total | 39 | 100.0% |
Screening Eligibility
| screen_eligible_conf | Rhodes | Karen | Riruta | Total |
|---|---|---|---|---|
| Yes | 146 | 108 | 56 | 310 |
| No | 635 | 260 | 170 | 1065 |
The table below show the total number of participants screened, eligible and those not eligible this week
| screen_eligible_conf | Rhodes | Karen | Riruta | Total |
|---|---|---|---|---|
| Yes | 1 | 3 | 5 | 9 |
| No | 16 | 9 | 5 | 30 |
ELigible and Consented partcipants
| screen_consent_yn | Rhodes | Karen | Riruta | Total |
|---|---|---|---|---|
| Yes | 146 | 99 | 49 | 294 |
| No | 0 | 9 | 20 | 29 |
| NA | 635 | 260 | 157 | 1052 |
Removed all NAs from the data above
| screened$screen_consent_yn | n | percent |
|---|---|---|
| Yes | 294 | 91.0% |
| No | 29 | 9.0% |
| Total | 323 | - |
The table below show the total number of participnats consented to the study this week
| screen_consent_yn | Rhodes | Karen | Riruta | Total |
|---|---|---|---|---|
| Yes | 1 | 2 | 5 | 8 |
| No | 0 | 1 | 4 | 5 |
| NA | 16 | 9 | 1 | 26 |
| enrol_phc_ke | Positive | Negative | Trace | Indeterminate | No sputum |
|---|---|---|---|---|---|
| Rhodes | 72 | 74 | 0 | 0 | 0 |
| Karen | 4 | 89 | 0 | 0 | 6 |
| Riruta | 13 | 36 | 0 | 0 | 0 |
| Total | 89 | 199 | 0 | 0 | 6 |
| xpert_result | n | percent |
|---|---|---|
| Positive | 89 | 30% |
| Negative | 199 | 68% |
| Trace | 0 | 0% |
| Indeterminate | 0 | 0% |
| No sputum | 6 | 2% |
| Total | 294 | - |
| Positive | Negative | Trace | Indeterminate | No sputum |
|---|---|---|---|---|
| Rhodes | ||||
| 49.3% (72) | 50.7% (74) | 0.0% (0) | 0.0% (0) | 0.0% (0) |
| Karen | ||||
| 4.0% (4) | 89.9% (89) | 0.0% (0) | 0.0% (0) | 6.1% (6) |
| Riruta | ||||
| 26.5% (13) | 73.5% (36) | 0.0% (0) | 0.0% (0) | 0.0% (0) |
| Total | ||||
| 30.3% (89) | 67.7% (199) | 0.0% (0) | 0.0% (0) | 2.0% (6) |
| enrol_phc_ke | n | percent |
|---|---|---|
| Rhodes | 146 | 50.0% |
| Karen | 99 | 30.0% |
| Riruta | 49 | 20.0% |
| Total | 294 | 100.0% |
| enrol_phc_ke | n | percent |
|---|---|---|
| Rhodes | 1 | 11.1% |
| Karen | 2 | 22.2% |
| Riruta | 6 | 66.7% |
| Total | 9 | 100.0% |
| obs_phc_ke | n | percent |
|---|---|---|
| Rhodes | 70 | 38.9% |
| Karen | 79 | 43.9% |
| Riruta | 31 | 17.2% |
| Total | 180 | 100.0% |
| obs_phc_ke | n | percent |
|---|---|---|
| Rhodes | 1 | 16.7% |
| Karen | 2 | 33.3% |
| Riruta | 3 | 50.0% |
| Total | 6 | 100.0% |
| obs_phc_ke | n |
|---|---|
| Rhodes | 19 |
| Karen | 27 |
| Total | 46 |
| obs_phc_ke | n |
|---|---|
| Karen | 3 |
| Total | 3 |
| exit_reason | n |
|---|---|
| Completed all follow up (26 week visit and MGIT result feedback) | 12 |
| Study withdrawal | 5 |
| Lost to follow up (missed visit procedures completed) | 6 |
| Notified of participant death | 4 |
| Other | 21 |
| No longer eligible (baseline Xpert positive) | 85 |
| No longer eligible (baseline MGIT positive) | 7 |
| Total | 140 |
| exit_reason | exit_reason_detail | n |
|---|---|---|
| Other | LAM positive results | 1 |
| Other | LAM positive results | 1 |
| Other | Missed baselines cohort visit within study window | 1 |
| Other | Out of window period | 3 |
| Other | Outside the window period | 1 |
| Other | Outside the window period | 7 |
| Other | Outside window period | 1 |
| Other | Outside window period | 1 |
| Other | Participant could not attend the baseline cohort visit within the study window | 1 |
| Other | Participant realised she was pregnant | 1 |
| Other | Participant urine lam turned positive | 1 |
| Other | Participant was not feeling well during the window period of cohort enrollment | 1 |
| Other | Work related matters | 1 |
| Total | - | 21 |
| exit_reason | n | percent |
|---|---|---|
| Completed all follow up (26 week visit and MGIT result feedback) | 12 | 36.4% |
| Study withdrawal | 1 | 3.0% |
| Lost to follow up (missed visit procedures completed) | 6 | 18.2% |
| Notified of participant death | 4 | 12.1% |
| Other | 3 | 9.1% |
| No longer eligible (baseline Xpert positive) | 0 | 0.0% |
| Not selected for cohort | 0 | 0.0% |
| No longer eligible (baseline MGIT positive) | 7 | 21.2% |
| Total | 33 | 100.0% |
| exit_reason | exit_reason_detail | n |
|---|---|---|
| Other | LAM positive results | 1 |
| Other | LAM positive results | 1 |
| Other | Participant urine lam turned positive | 1 |
| Total | - | 3 |
| obs_phc_ke | n |
|---|---|
| Rhodes | 60 |
| Karen | 58 |
| Riruta | 29 |
| Total | 147 |